{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:18:35Z","timestamp":1790036315518,"version":"4.0.1"},"reference-count":94,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1016\/j.amjmed.2009.12.008","type":"journal-article","created":{"date-parts":[[2010,3,5]],"date-time":"2010-03-05T04:32:26Z","timestamp":1267763546000},"page":"S38-S48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":96,"special_numbering":"S","title":["Overview of Newer Agents: Where Treatment Is Going"],"prefix":"10.1016","volume":"123","author":[{"given":"Ralph A.","family":"DeFronzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2009.12.008_bib1","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2337\/diab.37.6.667","article-title":"The triumvirate: \u03b2-cell, muscle, liver: a collusion responsible for NIDDM [Lilly lecture 1987]","volume":"37","author":"DeFronzo","year":"1988","journal-title":"Diabetes"},{"key":"10.1016\/j.amjmed.2009.12.008_bib2","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2337\/db09-9028","article-title":"From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus [Banting Lecture]","volume":"58","author":"DeFronzo","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.amjmed.2009.12.008_bib3","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1210\/jc.2005-1159","article-title":"The effect of rosiglitazone on the liver: decreased gluconeogenesis in patients with type 2 diabetes","volume":"91","author":"Gastaldelli","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.amjmed.2009.12.008_bib4","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.2337\/db05-1200","article-title":"Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study","volume":"55","author":"Abdul-Ghani","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.amjmed.2009.12.008_bib5","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.1210\/jc.2003-031941","article-title":"Separate contribution of diabetes, total fat mass, and fat topography to glucose production, gluconeogenesis, and glycogenolysis","volume":"89","author":"Gastaldelli","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.amjmed.2009.12.008_bib6","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/0026-0495(90)90168-C","article-title":"Impaired glucose tolerance and diabetes in obesity: a 6-year follow-up study of glucose metabolism","volume":"39","author":"Jallut","year":"1990","journal-title":"Metabolism"},{"key":"10.1016\/j.amjmed.2009.12.008_bib7","doi-asserted-by":"crossref","first-page":"610","DOI":"10.2337\/diacare.13.6.610","article-title":"Glucose toxicity","volume":"13","author":"Rossetti","year":"1990","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjmed.2009.12.008_bib8","doi-asserted-by":"crossref","first-page":"863","DOI":"10.2337\/diab.44.8.863","article-title":"Lipotoxicity in the pathogenesis of obesity-dependent NIDDM: genetic and clinical implications","volume":"44","author":"Unger","year":"1995","journal-title":"Diabetes"},{"key":"10.1016\/j.amjmed.2009.12.008_bib9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00125-003-1263-9","article-title":"\u03b2-Cell dysfunction and glucose intolerance: results from the San Antonio Metabolism (SAM) Study","volume":"47","author":"Gastaldelli","year":"2004","journal-title":"Diabetologia"},{"key":"10.1016\/j.amjmed.2009.12.008_bib10","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1210\/jc.2004-1133","article-title":"\u03b2-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis","volume":"90","author":"Ferrannini","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.amjmed.2009.12.008_bib11","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2337\/diabetes.52.1.102","article-title":"\u03b2-Cell deficit and increased \u03b2-cell apoptosis in humans with type 2 diabetes","volume":"52","author":"Butler","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.amjmed.2009.12.008_bib12","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1464-5491.2007.02043.x","article-title":"The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program","volume":"24","year":"2007","journal-title":"Diabet Med"},{"key":"10.1016\/j.amjmed.2009.12.008_bib13","doi-asserted-by":"crossref","first-page":"464","DOI":"10.2337\/dc07-1796","article-title":"Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA\/KORA Augsburg Surveys S2 and S3","volume":"31","author":"Ziegler","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjmed.2009.12.008_bib14","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1172\/JCI109394","article-title":"Insulin sensitivity and insulin binding to monocytes in maturity-onset diabetes","volume":"63","author":"DeFronzo","year":"1979","journal-title":"J Clin Invest"},{"key":"10.1016\/j.amjmed.2009.12.008_bib15","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1172\/JCI111938","article-title":"Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus","volume":"76","author":"DeFronzo","year":"1985","journal-title":"J Clin Invest"},{"key":"10.1016\/j.amjmed.2009.12.008_bib16","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/0026-0495(89)90129-7","article-title":"Fasting hyperglycemia in non-insulin dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue uptake","volume":"38","author":"DeFronzo","year":"1989","journal-title":"Metabolism"},{"key":"10.1016\/j.amjmed.2009.12.008_bib17","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/BF00253736","article-title":"Hepatic and peripheral insulin resistance: a common feature of insulin-independent and insulin-dependent diabetes","volume":"23","author":"DeFronzo","year":"1982","journal-title":"Diabetologia"},{"key":"10.1016\/j.amjmed.2009.12.008_bib18","first-page":"E214","article-title":"The glucose clamp technique: a method for quantifying insulin secretion and resistance","volume":"237","author":"DeFronzo","year":"1979","journal-title":"Am J Physiol"},{"key":"10.1016\/j.amjmed.2009.12.008_bib19","doi-asserted-by":"crossref","first-page":"E92","DOI":"10.1152\/ajpendo.00617.2005","article-title":"Muscle glucose transport and phosphorylation in type 2 diabetic, obese nondiabetic, and genetically predisposed individuals","volume":"292","author":"Pendergrass","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.amjmed.2009.12.008_bib20","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S1071-3581(03)00520-8","article-title":"Metabolic and molecular basis of insulin resistance","volume":"10","author":"Bajaj","year":"2003","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.amjmed.2009.12.008_bib21","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.2337\/diabetes.50.11.2572","article-title":"Skeletal muscle insulin resistance in normoglycemic subjects with a strong family history of type 2 diabetes is associated with decreased insulin-stimulated IRS-1 tyrosine phosphorylation","volume":"50","author":"Pratipanawatr","year":"2001","journal-title":"Diabetes"},{"key":"10.1016\/j.amjmed.2009.12.008_bib22","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1172\/JCI7535","article-title":"Insulin resistance differentially affects the PI 3- kinase\u2013 and MAP kinase\u2013mediated signaling in human muscle","volume":"105","author":"Cusi","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1016\/j.amjmed.2009.12.008_bib23","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.2337\/diabetes.52.8.1943","article-title":"Rosiglitazone improves downstream insulin receptor signaling in type diabetic patients","volume":"52","author":"Miyazaki","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.amjmed.2009.12.008_bib24","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.2337\/diabetes.53.7.1782","article-title":"Population-based incidence rates and risk factors for type 2 diabetes in white individuals: the Bruneck Study","volume":"53","author":"Bonora","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.amjmed.2009.12.008_bib25","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0002-9343(97)00027-2","article-title":"Insulin resistance implications for type II diabetes mellitus and coronary heart disease","volume":"103","author":"Haffner","year":"1997","journal-title":"Am J Med"},{"key":"10.1016\/j.amjmed.2009.12.008_bib26","doi-asserted-by":"crossref","first-page":"166","DOI":"10.2337\/diabetes.54.1.166","article-title":"Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes","volume":"54","author":"Lyssenko","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.amjmed.2009.12.008_bib27","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.2337\/diacare.25.7.1177","article-title":"Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study","volume":"25","author":"Hanley","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjmed.2009.12.008_bib28","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.2337\/diabetes.54.11.3252","article-title":"Insulin resistance, the metabolic syndrome, and incident cardiovascular events in the Framingham Offspring Study","volume":"54","author":"Rutter","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.amjmed.2009.12.008_bib29","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/414799a","article-title":"Insulin signaling and the regulation of glucose and lipid metabolism","volume":"414","author":"Saltiel","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.amjmed.2009.12.008_bib30","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/nrm1837","article-title":"Critical nodes in signaling pathways: insights into insulin action","volume":"7","author":"Taniguchi","year":"2006","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.amjmed.2009.12.008_bib31","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1172\/JCI117621","article-title":"Nitric oxide release accounts for insulin's vascular effects in humans","volume":"94","author":"Scherrer","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/j.amjmed.2009.12.008_bib32","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1172\/JCI117433","article-title":"Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent: a novel action of insulin to increase nitric oxide release","volume":"94","author":"Steinberg","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/j.amjmed.2009.12.008_bib33","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1161\/01.CIR.101.13.1539","article-title":"Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells","volume":"101","author":"Zeng","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2009.12.008_bib34","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/00004872-200502000-00001","article-title":"Endothelial function and dysfunction","volume":"23","author":"Brunner","year":"2005","journal-title":"J Hypertens"},{"key":"10.1016\/j.amjmed.2009.12.008_bib35","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1161\/01.ATV.14.5.746","article-title":"Long-term inhibition of NO synthesis promotes atherosclerosis in the hypercholesterolemic rabbit thoracic aorta: PGH2 does not contribute to impaired endothelium-dependent relaxation","volume":"14","author":"Naruse","year":"1994","journal-title":"Arterioscler Thromb"},{"issue":"suppl","key":"10.1016\/j.amjmed.2009.12.008_bib36","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.amjmed.2009.03.003","article-title":"The impact of nitric oxide in cardiovascular medicine: untapped potential utility","volume":"122","author":"Pepine","year":"2009","journal-title":"Am J Med"},{"issue":"pt 3","key":"10.1016\/j.amjmed.2009.12.008_bib37","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1042\/bj3330471","article-title":"Phosphoinositide 3-kinase: the key switch mechanism in insulin signaling","volume":"333","author":"Shepherd","year":"1998","journal-title":"Biochem J"},{"key":"10.1016\/j.amjmed.2009.12.008_bib38","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2337\/diacare.14.3.173","article-title":"Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and ASCVD","volume":"14","author":"DeFronzo","year":"1991","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjmed.2009.12.008_bib39","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1172\/JCI111764","article-title":"Receptors and growth promoting effects of insulin and insulin like growth factors on cells from bovine retinal capillaries and aorta","volume":"75","author":"King","year":"1985","journal-title":"J Clin Invest"},{"key":"10.1016\/j.amjmed.2009.12.008_bib40","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.2337\/diabetes.53.11.2735","article-title":"Molecular mechanisms of insulin resistance that impact cardiovascular biology","volume":"53","author":"Wang","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.amjmed.2009.12.008_bib41","doi-asserted-by":"crossref","first-page":"20801","DOI":"10.1074\/jbc.270.35.20801","article-title":"Mitogen-activated protein kinase inhibition does not block the stimulation of glucose utilization by insulin","volume":"270","author":"Lazar","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.amjmed.2009.12.008_bib42","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1210\/jc.2004-0745","article-title":"Insulin resistance is associated with impaired nitric oxide synthase activity in skeletal muscle of type 2 diabetic subjects","volume":"90","author":"Kashyap","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.amjmed.2009.12.008_bib43","doi-asserted-by":"crossref","first-page":"134","DOI":"10.2337\/dc07-1198","article-title":"Insulin reduces plasma arginase activity in type 2 diabetic patients","volume":"31","author":"Kashyap","year":"2008","journal-title":"Diabetes Care"},{"issue":"pt 1","key":"10.1016\/j.amjmed.2009.12.008_bib44","first-page":"E187","article-title":"Hemodynamic actions of insulin","volume":"267","author":"Baron","year":"1994","journal-title":"Am J Physiol"},{"key":"10.1016\/j.amjmed.2009.12.008_bib45","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/dmrr.634","article-title":"Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases","volume":"22","author":"Cersosimo","year":"2006","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.amjmed.2009.12.008_bib46","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1161\/01.CIR.0000164232.62768.51","article-title":"Coronary circulatory dysfunction in insulin resistance, impaired glucose tolerance, and type 2 diabetes mellitus","volume":"111","author":"Prior","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2009.12.008_bib47","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/362801a0","article-title":"The pathogenesis of atherosclerosis: a perspective for the 1990s","volume":"362","author":"Ross","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.amjmed.2009.12.008_bib48","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.amjmed.2004.02.042","article-title":"Insulin resistance and the endothelium","volume":"117","author":"Hsueh","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.amjmed.2009.12.008_bib49","doi-asserted-by":"crossref","first-page":"40L","DOI":"10.1016\/S0002-9149(02)02963-6","article-title":"Endothelial function: from vascular biology to clinical applications","volume":"90","author":"Behrendt","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjmed.2009.12.008_bib50","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.2337\/db06-0391","article-title":"Molecular mechanisms of insulin resistance: serine phosphorylation of insulin receptor substrate-1 and increased expression of p85\u03b1: the two sides of a coin","volume":"55","author":"Draznin","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.amjmed.2009.12.008_bib51","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1210\/endo.137.10.8828504","article-title":"Comparison of the insulin and insulin-like growth factor-1 mitogenic intracellular signaling pathways","volume":"137","author":"Sasaoka","year":"1996","journal-title":"Endocrinology"},{"key":"10.1016\/j.amjmed.2009.12.008_bib52","doi-asserted-by":"crossref","first-page":"21J","DOI":"10.1016\/S0002-9149(99)00353-7","article-title":"Insulin signaling in the arterial wall","volume":"84","author":"Hsueh","year":"1999","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjmed.2009.12.008_bib53","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1210\/jc.2003-030723","article-title":"Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach","volume":"89","author":"Bays","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.amjmed.2009.12.008_bib54","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1210\/jcem-72-1-96","article-title":"The role of free fatty acid metabolism in the pathogensis of insulin resistance in obesity and non-insulin dependent diabetes mellitus","volume":"72","author":"Groop","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.amjmed.2009.12.008_bib55","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.2337\/diabetes.54.6.1640","article-title":"Dose response effect of elevated plasma FFA on insulin signaling","volume":"54","author":"Belfort","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.amjmed.2009.12.008_bib56","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.2337\/diabetes.52.10.2461","article-title":"A sustained increase in plasma free fatty acids impairs insulin secretion in non-diabetic subjects genetically predisposed to develop type 2 diabetes","volume":"52","author":"Kashyap","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.amjmed.2009.12.008_bib57","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/BF02427280","article-title":"Reduced incretin effect in type 2 (non-insulin-dependent) diabetes","volume":"29","author":"Nauck","year":"1986","journal-title":"Diabetologia"},{"key":"10.1016\/j.amjmed.2009.12.008_bib58","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1210\/jcem.86.8.7750","article-title":"Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients","volume":"86","author":"Toft-Nielsen","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.amjmed.2009.12.008_bib59","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1586\/17446651.1.3.329","article-title":"Exenatide: first-in-class incretin mimetic for the treatment of type 2 diabetes mellitus","volume":"1","author":"Triplitt","year":"2006","journal-title":"Expert Rev Endocrinol Metab"},{"key":"10.1016\/j.amjmed.2009.12.008_bib60","doi-asserted-by":"crossref","first-page":"274","DOI":"10.2337\/diab.36.3.274","article-title":"Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics","volume":"36","author":"Baron","year":"1987","journal-title":"Diabetes"},{"key":"10.1016\/j.amjmed.2009.12.008_bib61","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1053\/meta.2002.34700","article-title":"Glucagon dose response curve for hepatic glucose production and glucose disposal in type 2 diabetic patients and normal individuals","volume":"51","author":"Matsuda","year":"2002","journal-title":"Metabolism"},{"key":"10.1016\/j.amjmed.2009.12.008_bib62","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.2337\/diabetes.54.12.3427","article-title":"Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes","volume":"54","author":"Rahmoune","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.amjmed.2009.12.008_bib63","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3109\/00365517109090668","article-title":"Maximum tubular reabsorption capacity for glucose and renal hemodynamics during rapid hypertonic glucose infusion in normal and diabetic subjects","volume":"28","author":"Mogensen","year":"1971","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1016\/j.amjmed.2009.12.008_bib64","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/diabetes.48.9.1801","article-title":"Altered hypothalamic function in response to glucose ingestion in obese humans","volume":"48","author":"Matsuda","year":"1999","journal-title":"Diabetes"},{"key":"10.1016\/j.amjmed.2009.12.008_bib65","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.2337\/dc05-2445","article-title":"The effect of pioglitazone on the liver: role of adiponectin","volume":"29","author":"Gastaldelli","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjmed.2009.12.008_bib66","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s00125-007-0698-9","article-title":"Effects of peroxisome proliferator-activated receptor (PPAR)-\u03b1 and PPAR-\u03b3 agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus","volume":"50","author":"Bajaj","year":"2007","journal-title":"Diabetologia"},{"key":"10.1016\/j.amjmed.2009.12.008_bib67","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1172\/JCI200112954","article-title":"Central melanocortin receptors regulate insulin action","volume":"108","author":"Obici","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1016\/j.amjmed.2009.12.008_bib68","doi-asserted-by":"crossref","first-page":"710","DOI":"10.2337\/diacare.24.4.710","article-title":"Improved glycemic control and enhanced insulin sensitivity in liver and muscle in type 2 diabetic subjects treated with pioglitazone","volume":"24","author":"Miyazaki","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjmed.2009.12.008_bib69","first-page":"89","article-title":"Metformin: a review of its metabolic effects","volume":"6","author":"Cusi","year":"1998","journal-title":"Diabetes Rev"},{"key":"10.1016\/j.amjmed.2009.12.008_bib70","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1056\/NEJM199508313330902","article-title":"Efficacy of metformin in patients with non-insulin dependent diabetes mellitus","volume":"333","author":"DeFronzo","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2009.12.008_bib71","doi-asserted-by":"crossref","first-page":"E871","DOI":"10.1152\/ajpendo.00551.2006","article-title":"Thiazolidinediones improve \u03b2-cell function in type 2 diabetic patients","volume":"292","author":"Gastaldelli","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.amjmed.2009.12.008_bib72","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2009.12.008_bib73","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","article-title":"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy","volume":"355","author":"Kahn","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2009.12.008_bib74","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2009.12.008_bib75","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1001\/jama.296.21.joc60158","article-title":"Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial","volume":"296","author":"Mazzone","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2009.12.008_bib76","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.2337\/diabetes.51.9.2796","article-title":"Preservation of pancreatic \u03b2-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women","volume":"51","author":"Buchanan","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.amjmed.2009.12.008_bib77","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S0140-6736(06)69420-8","article-title":"Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial","volume":"368","author":"Gerstein","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2009.12.008_bib78","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.2337\/diabetes.54.4.1150","article-title":"Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program","volume":"54","author":"Knowler","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.amjmed.2009.12.008_bib79","unstructured":"DeFronzo RA, Barneji MA, Bray G, et al. ACTos NOW for the prevention of diabetes (ACT NOW) study. Late-breaking abstract presented at the 68th Annual Meeting of the American Diabetes Association; June 6-10, 2008; San Francisco, CA. (NO ABSTRACT AVAILABLE) Available at ClinicalTrails.gov:NCT00220961:NCT00220961."},{"key":"10.1016\/j.amjmed.2009.12.008_bib80","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2337\/diabetes.55.02.06.db05-1066","article-title":"Effect of pioglitazone on pancreatic \u03b2-cell function and diabetes risk in Hispanic women with prior gestational diabetes","volume":"55","author":"Xiang","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.amjmed.2009.12.008_bib81","doi-asserted-by":"crossref","first-page":"762","DOI":"10.2337\/dc08-1797","article-title":"One-year treatment with exenatide improves \u03b2-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial","volume":"32","author":"Bunck","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjmed.2009.12.008_bib82","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1001\/archinte.168.19.2088","article-title":"National trends in treatment of type 2 diabetes mellitus, 1994\u20132007","volume":"168","author":"Alexander","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjmed.2009.12.008_bib83","doi-asserted-by":"crossref","first-page":"7402","DOI":"10.1016\/S0021-9258(18)42531-8","article-title":"Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom: further evidence for an exendin receptor on dispersed acini from guinea pig pancreas","volume":"267","author":"Eng","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1016\/j.amjmed.2009.12.008_bib84","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1185\/030079908X253870","article-title":"Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years","volume":"24","author":"Klonoff","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.amjmed.2009.12.008_bib85","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2147\/vhrm.2006.2.1.69","article-title":"Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes","volume":"2","author":"Schnabel","year":"2006","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.amjmed.2009.12.008_bib86","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2337\/diacare.28.5.1092","article-title":"Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes","volume":"28","author":"DeFronzo","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjmed.2009.12.008_bib87","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1463-1326.2006.00589.x","article-title":"Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus","volume":"8","author":"Ratner","year":"2006","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.amjmed.2009.12.008_bib88","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1464-5491.2007.02333.x","article-title":"Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic \u03b2-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with type 2 diabetes mellitus","volume":"25","author":"Vilsb\u00f8ll","year":"2008","journal-title":"Diabet Med"},{"key":"10.1016\/j.amjmed.2009.12.008_bib89","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1210\/jc.2003-031907","article-title":"Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, reduces glucagons levels in type 2 diabetes","volume":"80","author":"Ahren","year":"2004","journal-title":"J Endocrinol Metab"},{"key":"10.1016\/j.amjmed.2009.12.008_bib90","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1007\/s00125-006-0416-z","article-title":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus","volume":"49","author":"Raz","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.amjmed.2009.12.008_bib91","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.2337\/dc06-0706","article-title":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone","volume":"29","author":"Charbonnel","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjmed.2009.12.008_bib92","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.clinthera.2006.10.007","article-title":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study","volume":"28","author":"Rosenstock","year":"2006","journal-title":"Clin Ther"},{"key":"10.1016\/j.amjmed.2009.12.008_bib93","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/MAJ.0b013e31818eb721","article-title":"Impact of sitagliptin on markers of \u03b2-cell function: a meta-analysis","volume":"337","author":"Riche","year":"2009","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.amjmed.2009.12.008_bib94","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/dc08-9025","article-title":"Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"32","author":"Nathan","year":"2009","journal-title":"Diabetes Care"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934309010791?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934309010791?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T08:52:37Z","timestamp":1757580757000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934309010791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":94,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["S0002934309010791"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2009.12.008","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overview of Newer Agents: Where Treatment Is Going","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2009.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Published by Excerpta Medica Inc.","name":"copyright","label":"Copyright"}]}}